CFGS
ALNY icon

Concourse Financial Group Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

Concourse Financial Group Securities’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5
Closed -$1.33K – 76
2024
Q4 		$1.33K Buy
5
+2
+67% +$526 ﹤0.01% 2061
2024
Q3 		$825 Sell
3
-19
-86% -$4.95K ﹤0.01% 2094
2024
Q2 		$5.35K Buy
22
+1
+5% +$158 ﹤0.01% 1856
2024
Q1 		$3.14K Sell
21
-5
-19% -$834 ﹤0.01% 1977
2023
Q4 		$4.98K Buy
26
+23
+767% +$3.92K ﹤0.01% 1849
2023
Q3 		$531 Buy
+3
New +$572 ﹤0.01% 2170
2022
Q2 		– Sell
-76
Closed -$10.8K – 2177
2022
Q1 		$12K Buy
76
+4
+6% +$609 ﹤0.01% 1627
2021
Q4 		$12K Buy
72
+30
+71% +$5.58K ﹤0.01% 1797
2021
Q3 		$8K Sell
42
-3
-7% -$563 ﹤0.01% 1937
2021
Q2 		$8K Buy
45
+2
+5% +$293 ﹤0.01% 1920
2021
Q1 		$6K Buy
+43
New +$6.47K ﹤0.01% 1906
2019
Q3 		– Sell
-360
Closed -$28.5K – 1746
2019
Q2 		$26K Buy
360
+200
+125% +$15.3K ﹤0.01% 1142
2019
Q1 		$14K Buy
+160
New +$13.4K ﹤0.01% 1383

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Concourse Financial Group Securities's ALNY Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 5 shares — an estimated $1.33K sold.

Concourse Financial Group Securities first reported a position in ALNY in Q1 2019 and held it in 13 quarters. The position peaked at $26K in Q2 2019. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Concourse Financial Group Securities reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Concourse Financial Group Securities sold 5 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $1.33K.
  • Concourse Financial Group Securities first reported a position in Alnylam Pharmaceuticals in Q1 2019 and held it in 13 quarters.
  • Concourse Financial Group Securities's Alnylam Pharmaceuticals position peaked at $26K in Q2 2019.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.